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Summary
Background Stents are an alternative treatment to carotid endarterectomy for symptomatic carotid stenosis, but 
previous trials have not established equivalent safety and eﬃ  cacy. We compared the safety of carotid artery stenting with 
that of carotid endarterectomy.
Methods The International Carotid Stenting Study (ICSS) is a multicentre, international, randomised controlled trial 
with blinded adjudication of outcomes. Patients with recently symptomatic carotid artery stenosis were randomly 
assigned in a 1:1 ratio to receive carotid artery stenting or carotid endarterectomy. Randomisation was by telephone call 
or fax to a central computerised service and was stratiﬁ ed by centre with minimisation for sex, age, contralateral occlusion, 
and side of the randomised artery. Patients and investigators were not masked to treatment assignment. Patients were 
followed up by independent clinicians not directly involved in delivering the randomised treatment. The primary outcome 
measure of the trial is the 3-year rate of fatal or disabling stroke in any territory, which has not been analysed yet. The 
main outcome measure for the interim safety analysis was the 120-day rate of stroke, death, or procedural myocardial 
infarction. Analysis was by intention to treat (ITT). This study is registered, number ISRCTN25337470.
Findings The trial enrolled 1713 patients (stenting group, n=855; endarterectomy group, n=858). Two patients in the 
stenting group and one in the endarterectomy group withdrew immediately after randomisation, and were not included 
in the ITT analysis. Between randomisation and 120 days, there were 34 (Kaplan-Meier estimate 4·0%) events of disabling 
stroke or death in the stenting group compared with 27 (3·2%) events in the endarterectomy group (hazard ratio [HR] 
1·28, 95% CI 0·77–2·11). The incidence of stroke, death, or procedural myocardial infarction was 8·5% in the stenting 
group compared with 5·2% in the endarterectomy group (72 vs 44 events; HR 1·69, 1·16–2·45, p=0·006). Risks of any 
stroke (65 vs 35 events; HR 1·92, 1·27–2·89) and all-cause death (19 vs seven events; HR 2·76, 1·16–6·56) were higher in 
the stenting group than in the endarterectomy group. Three procedural myocardial infarctions were recorded in the 
stenting group, all of which were fatal, compared with four, all non-fatal, in the endarterectomy group. There was one 
event of cranial nerve palsy in the stenting group compared with 45 in the endarterectomy group. There were also fewer 
haematomas of any severity in the stenting group than in the endarterectomy group (31 vs 50 events; p=0·0197).
Interpretation Completion of long-term follow-up is needed to establish the eﬃ  cacy of carotid artery stenting compared 
with endarterectomy. In the meantime, carotid endarterectomy should remain the treatment of choice for patients 
suitable for surgery.
Funding Medical Research Council, the Stroke Association, Sanoﬁ -Synthélabo, European Union.
Introduction
Carotid endarterectomy became the treatment of choice 
for patients with recently symptomatic, severe carotid 
artery stenosis after the publication of results from 
large randomised trials that compared endarterectomy 
with best medical treatment alone.1–3 The potential 
beneﬁ t of endovascular treatment (angioplasty with or 
without stenting) as an alternative to carotid 
endarterectomy was ﬁ rst highlighted by the Carotid and 
Vertebral Artery Transluminal Angioplasty Study 
(CAVATAS).4 This trial showed that endovascular 
treatment largely avoided the main complications of 
the endarterectomy incision (namely cranial nerve 
injury and severe haematoma). However, the rate of 
stroke or death within 30 days after treatment was high 
in both groups. Since completion of CAVATAS, stenting 
has largely replaced angioplasty, and stents and 
protection devices speciﬁ cally designed for the carotid 
artery have been introduced. Two large randomised 
trials comparing use of carotid stenting with endarter-
ectomy for symptomatic stenosis have subsequently 
published short-term outcomes and longer term 
results.5–8 The Stent-Protected Angioplasty versus 
Carotid Endarterectomy (SPACE) trial in symptomatic 
patients did not show non-inferiority of stenting 
compared with endarterectomy within 30 days after 
treatment and was stopped early for reasons of futility 
and cost.6 The Endarterectomy versus Stenting in 
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Patients with Symptomatic Severe Carotid Stenosis 
(EVA-3S) trial was stopped early because of a sig-
niﬁ cantly lower rate of periprocedural stroke or death 
in the endarterectomy group than in the stenting 
group.5 We report the short-term results of the Inter-
national Carotid Stenting Study (ICSS), a randomised 
trial comparing stenting versus endarter ectomy for 
recently symptomatic carotid artery stenosis.
Methods
Study centres and participants
ICSS is an international, multicentre, open, randomised 
controlled trial designed to compare the safety and long-
term eﬃ  cacy of carotid stenting and endarterectomy. The 
protocol was published in 20049 and is publically available 
on the trial website. ICSS was approved by the Northwest 
Multicentre Research Ethics Committee in the UK and 
participating centres had to obtain site-speciﬁ c approval 
from their local ethics committees. All patients provided 
written informed consent.
Participating centres had a team of investigators 
consisting of at least one neurologist or physician with 
an interest in stroke, a surgeon with experience in 
endarterectomy, and a physician or surgeon with 
expertise in carotid angiography, angioplasty, and 
stenting. All centres were required to hold regular 
multidisciplinary meetings between the investigators to 
discuss the management of patients with carotid 
stenosis. Investigators submitted their curriculum vitae 
and audit data that documented satisfactory training and 
results of carotid treatment to the credential committee. 
Centres were then enrolled as either experienced or 
supervised centres on the recom mendation of the 
committee. To qualify as experienced, a centre had to 
have a surgeon who had done at least 50 carotid 
operations (ten or more cases per year) and a physician 
or surgeon who had done a minimum of 50 stenting 
procedures, with at least ten cases in the carotid artery. 
Centres not fulﬁ lling these criteria joined as supervised 
centres and their trial procedures had to be proctored by 
an outside surgeon or interventionist, appointed by the 
trial steering committee, until the proctor was satisﬁ ed 
that the centre was proﬁ cient in undertaking the 
procedure. Supervised centres were promoted to 
experienced centres after randomisation and treatment 
of 20 cases within the trial if their results were deemed 
acceptable by the proctor and the credential committee.
Patients were eligible for enrolment if they were 
older than 40 years of age and had symptomatic 
atheromatous carotid artery stenosis measured as more 
than 50% by the North American Symptomatic Carotid 
Endarterectomy Trial criteria2 (or non-invasive 
equivalent) deemed to require treatment. Symptoms 
attributable to the randomised artery needed to have 
occurred within 12 months before randomisation.
Non-invasive imaging of the carotid artery, including 
duplex ultrasound, was acceptable for study entry. 
Catheter angiography before randomisation was not 
required. Exclusion criteria included major stroke 
without useful recovery of function, previous carotid 
endarterectomy or stenting in the randomised artery, 
contraindications for either treatment, and planned 
coronary artery bypass grafting or other major surgery.
At randomisation, patients had to be deemed suitable 
for both surgery and stenting by the investigators, who 
also had to be uncertain which of the two treatments 
was the best option for the patient. Patients unsuitable 
for stenting because of tortuous anatomy proximal or 
distal to the stenosis, visible thrombus, proximal 
common carotid artery stenosis, or internal carotid 
artery pseudo-occlusion were excluded, as were patients 
unsuitable for endarterectomy because of the distal site 
of the stenosis, a rigid neck, or risk factors for surgical 
complications. No record was kept of patients screened 
who were ineligible or treated outside the trial. It was 
recommended that patients randomised to stenting 
after non-invasive investigation, in which subsequent 
angiography before stenting showed one or more 
exclusion criteria, should have the procedure abandoned 
and be treated by surgery, if appropriate, or medical 
care alone. A similar approach was taken in patients 
randomised to surgery.
For the full protocol for this 
study see http://www.cavatas.
com
Figure 1: Trial proﬁ le
Data for the number of patients screened for eligibility were not recorded.
21 underwent no procedure
2 died before intended procedure
3 disabling stroke before intended 
procedure
9 artery occluded
1 artery less than 50% stenosed
3 medical contraindications
1 refused treatment
2 other reasons
16 underwent no procedure
1 disabling stroke before intended 
procedure
5 artery occluded
3 artery less than 50% stenosed
1 anatomy unsuitable
3 other medical contraindications
3 other reasons
9 crossed over to endarterectomy
2 anatomy unsuitable
3 medical contraindications
1 refused treatment
3 other reasons
15 crossed over to stenting
1 anatomy unsuitable
6 medical contraindications
4 refused treatment
4 other reasons
2 withdrew all consent immediately
after randomisation
1 withdrew all consent immediately
after randomisation
857 analysed by intention to treat up  
to 120 days after randomisation
853 analysed by intention to treat up 
to 120 days after randomisation
858 randomly assigned to
endarterectomy
855 randomly assigned to carotid 
artery stenting
828 procedure initiated and analysed 
per protocol up to 30 days after 
procedure
821 procedure initiated and analysed 
per protocol up to 30 days after  
procedure
1713 patients randomised
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Randomisation and masking 
Eligible patients were randomly assigned in a 1:1 ratio to 
receive carotid artery stenting or carotid endarterectomy 
by use of a computerised service provided by Oxford 
Clinical Trials Service Unit staﬀ  who were not involved 
in other parts of the trial. The allocated treatment was 
communicated to investigators or one of their research 
team by telephone or fax after they provided baseline 
data for the patient. Randomisation was stratiﬁ ed by 
centre with minimisation for sex, age, contralateral 
occlusion, and side of the randomised artery. Investigators 
were kept masked about the randomisation program to 
prevent them anticipating the next assignment. Patients 
and individuals who delivered the interventions were 
not masked to treatment assignment. Patients were 
followed up by independent clinicians who were not 
masked to treatment assignment but who were not 
directly involved in delivering the randomised treatment. 
Adjudication of outcomes was blinded. Apart from the 
trial statistician and the data monitoring committee, all 
investigators, including the chief investigator, remained 
masked to the results of the trial until after recruitment 
was completed. 
Procedures 
Carotid stenting or endarterectomy was deemed initiated 
if the patient had been given general or local anaesthetic 
in preparation for the intervention, even if the procedure 
was subsequently abandoned before stent deployment or 
endarterectomy. Stents and other devices used for carotid 
stenting were chosen at the discretion of the inter-
ventionist but had to have a CE mark. The protocol 
recommended that a cerebral protection device should be 
used whenever the local investigator thought that one 
could be used safely, but this was not mandatory. A 
combination of aspirin and clopidogrel to cover stenting 
procedures was recommended. Use of heparin and 
atropine or similar agent during the procedure was 
mandatory. Surgeons were free to use standard or 
eversion endarterectomy. The use of local or general 
anaesthesia, shunts, and patches was left to the discretion 
of the surgeon.
Outcome events and trial safety 
The protocol speciﬁ ed that patients should be seen before 
randomisation and then followed up 30 days after 
treatment, 6 months after randomisation, and then once 
a year after randomisation by a clinician who was not 
involved in the revascularisation procedure. At every visit, 
levels of impairment were assessed with the modiﬁ ed 
Rankin scale. Outcome events were reported in detail to 
the central oﬃ  ce by the local neurologist or stroke 
physician. Major outcome events were submitted to an 
independent external adjudicator, who was masked to 
treatment allocation and who determined the cause, 
severity, and duration of the event. If this assessment 
diﬀ ered from the initial assessment, a second external 
Stenting 
group (n=853)
Endarterectomy 
group (n=857)
Age (years) 70 (9) 70 (9)
Sex (male) 601 (70%) 606 (71%)
Vascular risk factors
Treated hypertension 587 (69%) 595 (69%)
Systolic blood pressure (mm Hg) 147 (24) 146 (24)
Diastolic blood pressure (mm Hg) 79 (12) 78 (13)
Cardiac failure 23 (3%) 47 (5%)
Angina in past 6 months 83 (10%) 77 (9%)
Previous myocardial infarction 151 (18%) 156 (18%)
Previous CABG 109 (13%) 116 (14%)
Atrial ﬁ brillation 57 (7%) 59 (7%)
Other cardiac embolic source 19 (2%) 16 (2%)
Type 2 diabetes mellitus 134 (16%) 147 (17%)
Type 1 diabetes mellitus 50 (6%) 40 (5%)
Peripheral artery disease 139 (16%) 136 (16%)
Current smoker 205 (24%) 198 (23%)
Ex-smoker 408 (48%) 424 (49%)
Treated hyperlipidaemia 522 (61%) 562 (66%)
Cholesterol (mmol/L) 4·8 (1·3) 4·9 (1·3)
Degree of symptomatic carotid stenosis*
50–69% 92 (11%) 76 (9%)
70–99% 761 (89%) 781 (91%)
Degree of contralateral stenosis*
<50% 565 (66%) 561 (65%)
50–69% 128 (15%) 142 (17%)
70–99% 105 (12%) 110 (13%)
Occluded 49 (6%) 37 (4%)
Unknown 6 (1%) 7 (1%)
Most recent ipsilateral event†
Amaurosis fugax 148 (17%) 142 (17%)
Transient ischaemic attack 273 (32%) 303 (35%)
Ischaemic hemispheric stroke 393 (46%) 376 (44%)
Retinal infarction 26 (3%) 23 (3%)
Unknown 13 (2%) 13 (2%)
Event <6 months before 
randomisation
826 (97%) 816 (95%)
Event 6–12 months before 
randomisation‡
27 (3%) 36 (4%)
Multiple ipsilateral symptoms 
before randomisation
330 (39%) 317 (37%)
Ipsilateral stroke before most recent 
ipsilateral event
131 (15%) 106 (12%)
Modiﬁ ed Rankin score at randomisation
0–2 756 (89%) 744 (87%)
3–5§ 81 (9%) 99 (12%)
Unknown 16 (2%) 14 (2%)
Data are number (%) or mean (SD). CABG=coronary artery bypass graft. *Degree 
of stenosis measured by North American Symptomatic Carotid Endarterectomy 
Trial2 method at randomisation centre. †If two events were reported on the same 
day, the more serious of the two was counted (stroke>retinal infarction>transient 
ischaemic attack>amaurosis fugax). ‡In three patients the event was more than 
12 months before randomisation and in two the date was unknown. §Some 
Rankin scores of 3 or more were caused by non-stroke disability.
Table 1: Baseline characteristics of patients
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adjudicator reviewed the event and any diﬀ erences were 
resolved by consensus.
The primary analysis speciﬁ ed in the protocol was the 
diﬀ erence between groups in long-term rate of fatal or 
disabling stroke in any territory. Long-term was deﬁ ned 
as 3 years and therefore data are not yet available for this 
analysis. Here, we report the ﬁ rst secondary analysis 
speciﬁ ed in the protocol: the diﬀ erences in mortality and 
morbidity between groups within 30 days of carotid 
treatment. The main endpoint for this analysis was 
deﬁ ned before analysis as any stroke, death, or procedural 
myocardial infarction. Secondary endpoints of particular 
interest were any stroke, any stroke or death, any stroke 
or procedural death, disabling stroke or death, and all-
cause death. Events relating to the various components 
of the main endpoint, cranial nerve palsies, and 
haematomas requiring surgery, transfusion, or extended 
hospital stay, were analysed.
Stroke was deﬁ ned as a rapidly developing clinical 
syndrome of focal disturbance of cerebral function 
lasting more than 24 h or leading to death with no 
apparent cause other than that of vascular origin. Stroke 
was classiﬁ ed as fatal if death attributed to stroke 
occurred within 30 days of onset of stroke. Stroke or 
cranial nerve palsy were classiﬁ ed as disabling if there 
was an increase in the Rankin score to 3 or more, 
attributable to the event at 30 days after onset. The 
remaining non-fatal strokes were classiﬁ ed as non-
disabling. Myocardial infarction was deﬁ ned by the 
presence of two of the following three criteria: speciﬁ c 
cardiac enzymes more than twice the upper limit of 
normal; history of chest discomfort for at least 30 min; 
or the development of speciﬁ c abnormalities 
(eg, Q waves) on a standard 12-lead electrocardiograph. 
Death or myocardial infarction was deﬁ ned as 
procedural if it occurred within 30 days of stenting or 
endarterectomy. Transient ischaemic attack was deﬁ ned 
as an acute disturbance of focal neurological function 
with symptoms lasting less than 24 h attributed to 
cerebrovascular disease, but was not included as an 
outcome event in the analyses reported here.
The rate of reported events at individual centres was 
monitored at the central oﬃ  ce. The independent data 
monitoring committee met on a regular basis to review 
the accumulating data and to monitor trial safety.
Statistical analysis 
A large diﬀ erence in outcomes between the stenting and 
endarterectomy groups was not expected and the sample 
size was calculated to provide a reasonable estimate of 
the treatment eﬀ ect. A sample size of 1500 patients from 
experienced centres was chosen on the basis that this 
would allow a 95% CI to be measured with a width of 
±3·3 percentage points for the diﬀ erence in risk of 
disabling stroke or death between treatment groups, 
based on an average of 12·5% of patients having the 
outcome. We also calculated that this sample size would 
allow a 95% CI to be measured with a width 
±3·0 percentage points for the secondary short-term 
outcome of 30-day stroke, death, or procedural 
myocardial infarction, on the basis of an average of 10% 
of patients having the outcome. 
Because some patients did not receive their allocated 
treatment and the timing of treatment after randomisation 
varied, we undertook two main analyses: an intention-to-
treat (ITT) analysis of all events occurring up to 120 days 
after randomisation and a per-protocol analysis of the 
procedural risk within 30 days of allocated treatment. All 
main analyses combined patients from experienced and 
supervised centres.
The ITT analysis included all randomised patients and 
compared those allocated to stenting with those allocated 
to endarterectomy, irrespective of whether they received 
their allocated treatment or not. All events between 
randomisation and 120 days were included in the ITT 
analysis, irrespective of whether they occurred within 
30 days of treatment or not. This analysis therefore 
compared the initial policy of referral for stenting with 
referral for endarterectomy in terms of outcome over 
Stenting group 
(n=828)
Endarterectomy 
group (n=821)
p value*
Time from randomisation to treatment (days) 9 (5–17) 11 (5–24) <0·0001
≤14 578 (70%) 469 (57%) ··
>14 250 (30%) 352 (43%) ··
Time from most recent event to treatment (days) 35 (15–82) 40 (18–87) 0·013
≤14 205 (25%) 151 (18%) ··
>14 623 (75%) 668 (81%) ··
Data are number (%) or median (IQR) in the per-protocol analysis. Three patients in the endarterectomy group were 
randomised more than 12 months after onset of symptoms. The date of the most recent event was unknown in two 
patients (endarterectomy group). *Mann-Whitney U test.
Table 2: Time from randomisation and from most recent ipsilateral event to allocated treatment
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Figure 2: Time between randomisation and treatment
Cumulative number of patients in whom allocated treatment was initiated per 
protocol plotted as a proportion of the total number randomised in each group 
(vertical axis), against the delay between the dates of randomisation and 
treatment (horizontal axis). Only allocated per-protocol treatment dates were 
counted.
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120 days. The period of 120 days was chosen because 
most patients should have had their treatment within 
3 months of randomisation and their 30-day post-
treatment follow-up appointment within 4 months after 
randomisation.
Patients with less than 120 days of follow-up and without 
an event were censored on the date of last follow-up. 
Censoring was assumed to be non-informative—
ie, a censored patient was assumed to have the same risk 
of an outcome event as those who had complete 120-day 
follow-up. Kaplan-Meier methods were used to estimate 
120-day probabilities of an event and subsequently the 
absolute risk diﬀ erence between the two treatment groups 
and corresponding 95% CIs. Cox proportional hazard 
methods were used to calculate the relative diﬀ erence 
between treatment groups (hazard ratio, HR) and 95% CIs 
with endarterectomy as the reference group. Log-rank 
tests were used to compare the two survival curves.
The 30-day per-protocol analysis of the procedural risk 
included only patients in whom the allocated treatment 
was initiated as their ﬁ rst ipsilateral revascularisation 
procedure. Patients who received the alternative 
revascularisation procedure as their ﬁ rst treatment 
(cross-overs), or who received no revascularisation 
treatment were excluded from this analysis. All outcome 
events occurring within 30 days after initiation of the ﬁ rst 
allocated treatment were included. We included every 
patient in whom the allocated treatment was initiated in 
the per-protocol analysis, even if the date of treatment 
was more than 120 days after randomisation, or if the 
treatment was aborted after initiation. This per-protocol 
analysis therefore compared the 30-day procedural risks 
of the two treatments in those patients in whom the 
allocated procedure was completed or initiated. Binomial 
regression methods were used to estimate the 30-day 
absolute risk diﬀ erences and relative risk ratios together 
with 95% CIs. χ² tests were used to test for diﬀ erences 
between the two treatment groups. 
Several predeﬁ ned exploratory subgroup analyses were 
undertaken to investigate whether the relative treatment 
eﬀ ect for the 120-day ITT short-term composite outcome 
of stroke, death, or procedural myocardial infarction 
diﬀ ered across various patient groups. Interaction tests 
were done with Cox proportional hazard models. All 
analyses were done with Stata release 11, apart from the 
meta-analysis, which was done with ReviewManager 
version 5.0. This study is registered, number 
ISRCTN25337470.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or the 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Figure 1 shows the trial proﬁ le. Between May, 2001, and 
October, 2008, 1713 patients from 50 academic centres in 
Europe, Australia, New Zealand, and Canada  were 
enrolled and randomised. Three patients (stenting group, 
two; endarterectomy group, one) withdrew consent 
immediately after randomisation and were excluded 
from the ITT analysis. 751 (88%) of 853 patients assigned 
to carotid stenting and 760 (89%) of 857 patients assigned 
to endarterectomy were randomised at centres classiﬁ ed 
as experienced. Table 1 shows baseline characteristics of 
study participants.
Most patients had their allocated treatment initiated 
(stenting group, n=828; endarterectomy group, n=821). 
Nine patients allocated to stenting crossed over to 
surgery without an attempt at the procedure and a 
further 16 had no attempted ipsilateral endarterectomy 
or stenting procedure (ﬁ gure 1). 15 patients allocated to 
endar terectomy crossed over to stenting without an 
attempt at endarterectomy and 21 had no attempted 
ipsilateral procedure.
Monitoring of adverse events led to concern about the 
stenting results of two investigators at supervised 
centres. These investigators were stopped from treating 
further patients within the trial and their centres were 
suspended from randomisation. All the patients 
allocated to stenting (n=11, ﬁ ve with disabling stroke or 
death) or endarterectomy during the same time period 
(n=9, one with fatal stroke) at these centres were 
included in the analyses. One of the two centres 
subsequently restarted randomisation with a diﬀ erent 
investigator performing stenting.
Stenting group 
(n=853)
Endarterectomy 
group (n=857)
Hazard ratio (95% CI) Risk diﬀ erence, 
% (95% CI)
p value*
Stroke, death or procedural myocardial infarction 72 (8·5%) 44 (5·2%) 1·69 (1·16 to 2·45) 3·3% (0·9 to 5·7) 0·006
Any stroke 65 (7·7%) 35 (4·1%) 1·92 (1·27 to 2·89) 3·5% (1·3 to 5·8) 0·002
Any stroke or death 72 (8·5%) 40 (4·7%) 1·86 (1·26 to 2·74) 3·8% (1·4 to 6·1) 0·001
Any stroke or procedural death 68 (8·0%) 36 (4·2%) 1·95 (1·30 to 2·92) 3·8% (1·5 to 6·0) 0·001
Disabling stroke or death 34 (4·0%) 27 (3·2%) 1·28 (0·77 to 2·11) 0·8% (–0·9 to 2·6) 0·34
All-cause death 19 (2·3%) 7 (0·8%) 2·76 (1·16 to 6·56) 1·4% (0·3 to 2·6) 0·017
Data are number of ﬁ rst events (Kaplan-Meier estimate at 120 days). Risk diﬀ erences are calculated from Kaplan-Meier estimates at 120 days. *Log-rank test.
Table 3: Outcome measures within 120 days of randomisation (intention-to-treat population)
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Figure 2 shows the delay from randomisation to ﬁ rst 
initiated ipsilateral treatment in the per-protocol analysis. 
Median delay from randomisation to treatment was 
shorter in the stenting group than in the endarterectomy 
group, as was the delay from most recent ipsilateral event 
to treatment (table 2).
Of the 828 patients in whom stenting was initiated as 
allocated, 64 (8%) had their procedure aborted before the 
insertion of a stent (38 procedures were aborted because 
of diﬃ  culty gaining access to the stenosis, 15 were 
aborted because of the ﬁ nding of an occluded artery, one 
patient had a fatal stroke, one patient had fatal myocardial 
infarction before completion of treatment, two had other 
medical complications, and further investigation in seven 
patients showed the artery to be <50% stenosed). Of the 
62 patients whose stenting procedure was aborted after 
initiation and who did not have a fatal event, 37 went 
on to have an ipsilateral endarterectomy, whereas 
25 continued with best medical care only. Only two of the 
821 patients whose allocated endarterectomy was initiated 
had their procedure aborted (one patient had an allergic 
reaction during general anaesthesia; the other became 
distressed and the endarterectomy had to be abandoned). 
Both patients subsequently had ipsilateral stenting.
The following stents were each used in 10% or more of 
the 764 patients in whom stents were inserted: Carotid 
A B
C
E F
D
All-cause death
853
857
0
2
4
6
8
10 HR 2·76 (95% CI 1·16–6·56), p=0·017
0
2
4
6
8
10 HR 1·86 (95% CI 1·26–2·74), p=0·001
0
2
4
6
8
10 HR 1·69 (95% CI 1·16–2·45), p=0·006
HR 1·95 (95% CI 1·30–2·92), p=0·001
HR 1·28 (95% CI 0·77–2·11), p=0·34
HR 1·92 (95% CI 1·27–2·89), p=0·002
837
851
Cu
m
ul
at
iv
e 
ris
k 
(%
)
Cu
m
ul
at
iv
e 
ris
k 
(%
)
Cu
m
ul
at
iv
e 
ris
k 
(%
)
803
818
793
806
788
802
853
857
792
826
753
792
743
778
738
771
0 30 60
Follow-up (days) Follow-up (days)
90 120 0 30 60 90 120
Number at risk
Stenting group
Endarterectomy
group
853
857
792
826
753
792
743
778
738
771
853
857
823
836
790
803
780
790
775
784
Number at risk
Stenting group
Endarterectomy
group
853
857
792
822
753
789
743
775
Stenting group
Endarterectomy group
738
768
853
857
792
826
753
792
743
778
736
771
Number at risk
Stenting group
Endarterectomy
group
Any stroke or procedural death
Stroke or death Disabling stroke or death
Stroke, death, or procedural myocardial infarction Any stroke
8·5%
7·7%
4·1%
5·2%
8·5%
4·0%
3·2%
8·0%
4·2%
4·7%
2·3%
0·8%
Figure 3: Kaplan-Meier estimates of cumulative incidence of various outcome measures
Data were analysed by intention to treat. The numbers above the end of the lines are the incidence estimates at 120 days after randomisation. HR=hazard ratio.
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Wallstent (Boston Scientiﬁ c), Precision (Cordis), and 
Protégé (EV3). The following were each used in less than 
10% of patients: Acculink (Guidant), Xact (Abbott), Smart 
(Cordis), Cristallo Ideale (Invatec), Exponent (Medtronic), 
Next Stent (Boston Scientiﬁ c). Protection devices were 
known to have been used in 593 (72%) of 828 patients. 
The following protection devices were each used in 10% 
or more of the patients in whom stenting was attempted: 
FilterWire EZ (Boston Scientiﬁ c), Angioguard (Cordis), 
Spider FX (EV3), and Emboshield (Abbott). A range of 
other protection devices were each used in less than 
5% of patients. In 27 patients, it was not clear whether or 
not a protection device was used.
In the ITT analysis, between randomisation and 
120 days, there was no signiﬁ cant diﬀ erence in the rate of 
disabling stroke or death between groups (stenting 
group, 4·0% vs endarterectomy group, 3·2%; table 3).
The risk of stroke, death, or procedural myocardial 
infarction 120 days after randomisation was signiﬁ cantly 
higher in patients in the stenting group than in patients 
in the endarterectomy group (8·5% vs 5·2%), representing 
an estimated 120-day absolute risk diﬀ erence of 3·3% 
(95% CI 0·9–5·7) with an HR in favour of surgery of 
1·69 (1·16–2·45, log-rank p=0·006; ﬁ gure 3, table 3). 
Most outcome events in the stent and endarterectomy 
groups occurred within 30 days of the ﬁ rst ipsilateral 
procedure (61 of 72 events vs 31 of 44 events). A few events 
occurred after randomisation but before the date of 
treatment (two patients vs one patient), or in patients 
who had no attempted ipsilateral procedure (three patients 
vs six patients), or more than 30 days after treatment but 
within 120 days of randomisation (six patients vs 
six patients).
Compared with endarterectomy, allocation to stenting 
had a greater 120-day risk of the outcome measures of 
any stroke, any stroke or death, any stroke or procedural 
death, and all-cause death (table 3). Most strokes within 
120 days of randomisation were ipsilateral to the treated 
carotid artery and most were ischaemic (table 4). There 
were very few haemorrhagic strokes with only two 
patients in whom the cause of the stroke was uncertain. 
The observed treatment eﬀ ect was largely driven by the 
higher number of non-disabling strokes in the stenting 
group, most of which had symptoms lasting for more 
than 7 days. There was an excess of fatal strokes in the 
stenting group compared with the surgery group, but 
little diﬀ erence in the number of patients with disabling 
stroke within 120 days of randomisation.
The per-protocol analysis included 1649 patients 
(stenting group, n=828; endarterectomy group, n=821). 
Results for 30-day procedural risk mirrored the results of 
the intention-to-treat analysis. Risk of stroke, death, or 
procedural myocardial infarction was higher in the 
stenting group than in the endarterectomy group (30-day 
risk 7·4% vs 4·0%; risk diﬀ erence [RD] 3·3%, 95% CI 
1·1–5·6; risk ratio [RR] 1·83, 1·21–2·77, χ² p=0·003; 
table 5). Risk of any stroke or death up to 30 days after 
treatment remained signiﬁ cantly higher in patients in 
whom stenting was initiated than in patients with surgery 
initiated, but there was no signiﬁ cant diﬀ erence in the 
risk of disabling stroke or death between treatment 
groups. There were more fatal strokes in the stenting 
group than in the endarterectomy group (eight vs three), 
but diﬀ erence in the risk of death alone was no longer 
signiﬁ cant (table 5). 43 (74%) of 58 strokes in the stenting 
group and 12 (44%) of 27 in the endarterectomy group 
occurred on the day of the procedure.
Few procedural myocardial infarctions were recorded 
(three in the stenting group, all of which were fatal, 
compared with ﬁ ve in the endarterectomy group). 
Cranial nerve palsies were almost completely avoided by 
stenting (table 4; RR 0·02, 95% CI 0·00–0·16, p<0·0001). 
The one cranial nerve palsy recorded in the stenting 
group occurred as a complication of an endarterectomy 
done within 30 days of stenting. This patient and one 
additional patient in the endarterectomy group required 
percutaneous endoscopic gastrostomy feeding as a 
ITT analysis (events up to 
120 days after randomisation)
Per-protocol analysis (events 
between 0 days and 30 days 
after treatment)
Stenting 
group 
(n=853)
Endarterectomy 
group (n=857)
Stenting 
group 
(n=828)
Endarterectomy 
group (n=821)
Any stroke 65* 35 58* 27
Ipsilateral stroke 58 30 52 25
Ischaemic stroke 63 28 56 21
Haemorrhagic stroke 3 5 2 5
Uncertain cause 0 2 0 1
Non-disabling stroke 39 14 36 11
Lasting fewer than 7 days 9† 5‡ 8† 5‡
Lasting more than 7 days 31 9 29 6
Disabling stroke 17§ 20 14 14
Fatal stroke 9 2 8 3
Procedural myocardial infarction 3 4 3 5
Non-fatal myocardial infarction 0 4 0 5¶
Fatal myocardial infarction 3 0 3 0
Death unrelated to stroke or 
myocardial infarction
7 5 1 1
Cranial nerve palsy 1|| 45 1|| 45
Disabling cranial nerve palsy 1|| 1 1|| 1
Haematoma 31 50 30 50
Severe haematoma** 9 28 8 28
Data are number of ﬁ rst events of each type. See text for deﬁ nition of per protocol. *In two patients this was a retinal 
infarction. One patient had both an ischaemic and a haemorrhagic stroke. †One patient had a subsequent fatal 
myocardial infarction and one patient also had a non-disabling stroke that lasted for more than 7 days. ‡One patient 
had a subsequent disabling stroke. §Two patients subsequently died of a cause unrelated to stroke or myocardial 
infarction. ¶One patient had a non-fatal myocardial infarction within 30 days of the ﬁ rst procedure, which was 
undertaken more than 120 days after randomisation. This myocardial infarction was therefore excluded from the 
ITT analysis (which stopped at 120 days) but was included in the per-protocol 30-day analysis that included all ﬁ rst 
ipsilateral allocated procedures. ||The cranial nerve palsy in this patient in the stenting group, which was initiated but 
aborted, occurred after endarterectomy done within 30 days of the stenting procedure. **Severe haematoma was 
deﬁ ned as one that required surgical evacuation or blood transfusion, or resulted in extended hospital stay.
Table 4: Number of outcome events between randomisation and 120 days in the intention-to-treat (ITT) 
analysis and between initiation of treatment and 30 days after treatment in the per-protocol analysis
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result of the cranial nerve palsies, which were classiﬁ ed 
as disabling. There were also fewer haematomas of any 
severity in the stenting group than in the endarterectomy 
group (table 4; RR 0·59, 0·38–0·93, p=0·0197), and 
fewer severe haematomas requiring surgical inter-
vention, blood transfusion, or extended hospital stay 
(table 4; RR 0·28, 0·13–0·62, p=0·0007).
A post-hoc sensitivity analysis was undertaken to 
examine if the results of the per-protocol analysis were 
aﬀ ected by inclusion of patients in whom the allocated 
procedure was initiated but not completed. Exclusion of 
the 64 patients allocated to stenting and two patients 
allocated to endarterectomy in whom the procedures 
were aborted after initiation—ie, including only patients 
in whom the allocated procedure was completed as 
planned—made little diﬀ erence to the results (30-day 
risk of stroke, death, or procedural myocardial infarction 
7·6% in the stenting group vs 4·0% in the endarterectomy 
group; RD 3·6%, 95% CI 1·3–5·9; RR 1·88, 1·24–2·86, 
p=0·002).
We undertook exploratory analyses of the composite 
outcome of stroke, death, or procedural myocardial 
infarction for predeﬁ ned subgroups (ﬁ gure 4). These 
analyses suggested that carotid stenting might have a 
similar risk to endarterectomy in women, but that the 
intervention was more hazardous than endarterectomy 
in men. The diﬀ erence was mainly caused by a higher 
risk of stroke, death, or procedural myocardial infarction 
in women assigned to endarterectomy than in men 
(7·6% vs 4·2%). However, the diﬀ erence between the 
hazard ratios comparing the risk of stenting with 
endarterectomy in men and women only reached 
borderline signiﬁ cance (interaction p=0·071). Stenting 
was more hazardous, and endarterectomy less hazardous, 
in patients without treated hypertension at baseline than 
in patients with treated hypertension (ﬁ gure 4). 
There was also a suggestion that patients allocated to 
the stenting group had a similar risk of stroke, death, or 
procedural myocardial infarction to those allocated to 
endarterectomy after multiple ipsilateral symptoms, but 
compared with patients with only one event before 
randomisation, the diﬀ erence in the hazard ratios only 
reached borderline signiﬁ cance (interaction p=0·055). 
There was no evidence that the relative increase in the 
hazard of an event in the stenting group compared with 
the endarterectomy group diﬀ ered signiﬁ cantly across 
any other subgroups.
Discussion
Short-term results from this randomised controlled trial 
show that carotid endarterectomy is safer than carotid 
stenting for treatment of patients with symptomatic 
carotid artery stenosis. Patients allocated to stenting had 
a 3·3% higher risk of stroke, death, or procedural 
myocardial infarction within 120 days of randomisation 
in the ITT analysis. In the per-protocol analysis, the rate 
of any stroke or death within 30 days of treatment in the 
stenting group was more than twice the rate recorded in 
the endarterectomy group. The diﬀ erence between 
groups in the per-protocol analysis was mainly 
attributable to an excess of non-disabling stroke in the 
stenting group compared with the endarterectomy 
group, but there were also more fatal strokes and fatal 
myocardial infarctions in the stenting group. By contrast, 
the numbers of disabling strokes in the two groups were 
identical and the rate of disabling stroke or death was 
not signiﬁ cantly diﬀ erent between groups.
Most strokes within 30 days of treatment were 
ipsilateral to the treated artery and most were ischaemic. 
Despite the recommended use of combined antiplatelet 
therapy with aspirin and clopidogrel before stenting and 
for 1 month afterwards, plus use of heparin during the 
procedure, there were only two haemorrhagic strokes 
within 30 days of stenting compared with ﬁ ve after 
endarterectomy, suggesting that dual antiplatelet 
therapy in this setting is safe. However, this anti-
thrombotic regimen did not reduce ischaemic stroke 
suﬃ  ciently in the stenting group.
The balance of risk in favour of surgery caused by an 
excess of non-disabling stroke in the stenting group 
might be seen as partly oﬀ set by the fact that 
endarterectomy was associated with more cranial nerve 
injuries and more severe haematomas than was stenting. 
However, the long-term outcome of non-disabling stroke 
might be worse than that of non-disabling cranial nerve 
palsy. A recent systematic review has highlighted the 
increased risk of dementia associated with recurrent 
stroke10 and the long-term consequences of the non-
Stenting group 
(n=828)
Endarterectomy 
group (n=821)
Risk ratio (95% CI) Risk diﬀ erence, 
% (95% CI)
p value*
Stroke, death, or myocardial infarction 61 (7·4%) 33 (4·0%) 1·83 (1·21 to 2·77) 3·3% (1·1 to 5·6) 0·003
Any stroke 58 (7·0%) 27 (3·3%) 2·13 (1·36 to 3·33) 3·7% (1·6 to 5·8) 0·001
Any stroke or death 61 (7·4%) 28 (3·4%) 2·16 (1·40 to 3·34) 4·0% (1·8 to 6·1) 0·0004
Disabling stroke or death 26 (3·1%) 18 (2·2%) 1·43 (0·79 to 2·59) 0·9% (–0·6 to 2·5) 0·23
Procedural death 11† (1·3%) 4 (0·5%) 2·73 (0·87 to 8·53) 0·8% (–0·1 to 1·8) 0·072
Data are number of ﬁ rst events (%). See text for deﬁ nition of per protocol. *χ² test. †One patient had a fatal stroke but died more than 30 days after the procedure. The event 
is therefore counted in the fatal stroke outcome but not in the procedural death outcome.
Table 5: Outcome measures between initiation of treatment and 30 days after treatment (per-protocol analysis)
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disabling strokes in our study might only become evident 
with further follow-up, which will include measures of 
disability and quality of life.
Patients who received a stent had a shorter wait from 
most recent stroke or transient ischaemic attack to 
treatment than did those who received endarterectomy, 
but even so only 25% of patients in the stenting group 
were treated within 14 days of symptoms, compared with 
18% of those in the endarterectomy group. However, 
there was no diﬀ erence in the risks of stenting compared 
with endarterectomy whether or not patients were treated 
within 14 days of symptoms or later. Several strokes 
occurred before treatment was initiated (ﬁ ve vs seven) 
and several patients developed asymptomatic carotid 
artery occlusion before treatment (ﬁ ve vs nine), 
emphasising the importance of treating carotid stenosis 
as soon as possible after symptoms.
The results of our study are consistent with those seen 
in previous randomised trials.11 A new analysis of events 
occurring within 30 days of treatment in CAVATAS also 
showed an excess of minor strokes in patients assigned 
to endovascular treatment compared with those assigned 
to endarterectomy, with no diﬀ erence in rates of disabling 
stroke or death.12 CAVATAS used outdated techniques 
and few patients had stents inserted. The ﬁ rst multicentre 
randomised trial of carotid stenting with modern devices 
designed for the carotid artery, the Stenting and 
Angioplasty with Protection in Patients at High Risk for 
Endarterectomy (SAPPHIRE) trial, mostly recruited 
patients with asymptomatic stenosis at high risk for 
endarterectomy.13 Therefore, the trial’s ﬁ ndings, which 
suggested that stenting was not inferior to 
endarterectomy, cannot be directly compared with our 
results. The EVA-3S and SPACE trials recruited only 
symptomatic patients and had similar protocols to our 
trial.5,6 We have therefore combined the published 30-day 
safety data from EVA-3S, SPACE, and ICSS in a meta-
analysis (ﬁ gure 5). The summary statistic strongly 
Age (years)
<70
≥70
Sex
Male
Female
Diabetes†
No
Yes
Treated hypertension†
No
Yes
Ipsilateral stenosis
50–69%
70–99%
Contralateral stenosis
0–49%
50–69%
70–99%
Occluded
Type of most recent event
Stroke
Transient ischaemic attack
Amaurosis fugax
Multiple ipsilateral symptoms
No
Yes
Centre experience
Experienced
Supervised
Centre recruitment
<50 patients
≥50 patients
Time from event to treatment‡
≤14 days
>14 days
 21/394 (5·4%)
 51/459 (11·2%)
 52/601 (8·7%)
 20/252 (8·0%)
 51/659 (7·8%)
 19/184 (10·4%)
 25/256 (9·8%)
 45/587 (7·7%)
 4/92 (4·4%)
 68/761 (9·0%)
 45/565 (8·0%)
 14/128 (11·0%)
 9/105 (8·7%)
 2/49 (4·3%)
 45/419 (10·8%)
 24/273 (8·8%)
 3/148 (2·0%)
 52/523 (10·0%)
 20/330 (6·1%)
 65/751 (8·7%)
 7/102 (6·9%)
 33/302 (11·0%)
 39/551 (7·1%)
 15/205 (7·3%)
 46/623 (7·4%)
 
 15/404 (3·7%)
 29/453 (6·5%)
 25/606 (4·2%)
 19/251 (7·6%)
 32/663 (4·9%)
 12/187 (6·5%)
 8/255 (3·2%)
 36/595 (6·1%)
 3/76 (4·0%)
 41/781 (5·3%)
 27/561 (4·8%)
 8/142 (5·7%)
 7/110 (6·4%)
 1/37 (2·7%)
 21/399 (5·3%)
 16/303 (5·3%)
 5/142 (3·5%)
 25/540 (4·7%)
 19/317 (6·0%)
 38/760 (5·0%)
 6/97 (6·6%)
 14/307 (4·6%)
 30/550 (5·5%)
 5/151 (3·3%)
 28/668 (4·2%)
0·62
0·071
0·97
0·039
0·584
0·741
0·157
0·055
0·444
0·102
0·68
1·46 (0·75–2·84)
1·79 (1·14–2·83)
2·17 (1·35–3·50)
1·05 (0·56–1·97)
1·64 (1·05–2·55)
1·67 (0·81–3·43)
3·25 (1·46–7·20)
1·29 (0·83–2·00)
1·13 (0·25–5·04)
1·75 (1·19–2·58)
1·70 (1·05–2·73)
2·04 (0·85–4·85)
1·37 (0·51–3·68)
1·51 (0·14–16·61)
2·12 (1·26–3·55)
1·71 (0·91–3·22)
0·57 (0·14–2·40)
2·22 (1·38–3·58)
1·03 (0·55–1·92)
1·78 (1·19–2·65)
1·13 (0·38–3·35)
2·51 (1·35–4·70)
1·32 (0·82–2·12)
2·21 (0·82–5·95)
1·76 (1·12–2·78)
Stenting
Number of events/
number of patients (%)*
Endarterectomy
Number of events/
number of patients (%)*
Hazard ratio (95% CI)
Interaction
p value
Favours endarterectomyFavours stenting
0·3 0·5 0·75 1·0 1·5 2·0 3·0 4·0 5·0 7·0
Figure 4: Subgroup analysis to compare the rates of stroke, death, or procedural myocardial infarction in diﬀ erent subgroups
Subgroups are deﬁ ned according to baseline characteristics and analysed by intention to treat up to 120 days after randomisation, apart from time from event to 
treatment, which is analysed per protocol. p values are associated with treatment-covariate interaction tests. *Data are number of events of ﬁ rst stroke, death, or 
procedural myocardial infarction within 120 days of randomisation/number of patients (Kaplan-Meier estimate at 120 days). †Patients with missing information 
were excluded from the analysis. ‡Time from the most recent ipsilateral event before randomisation to the date of treatment, analysed per protocol for 30-day 
procedural events only (results are relative risk and 95% CI at 30 days after treatment).
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favours carotid endarterectomy (odds ratio for stroke, 
death, or myocardial infarction within 30 days after the 
procedure 1·73, 95% CI 1·29–2·32). One further large 
randomised trial, the Carotid Revascularization 
Endarterectomy vs Stenting Trial (CREST), has completed 
recruitment, but has not yet published any safety data.14
Since CAVATAS was completed, there has been a 
reduction in risk of adverse outcomes associated with 
endovascular treatment, but the risk associated with 
endarterectomy has reduced to a greater extent. The risk 
of stroke, death, or procedural myocardial infarction in 
the stenting group of our trial is similar to the risk 
associated with carotid endarterectomy that was reported 
in the European Carotid Surgery Trial (ECST) in 1998.1 By 
contrast, the risk of stroke, death, or procedural 
myocardial infarction after endarterectomy in our trial 
and in EVA-3S was approximately half that reported in 
ECST. This reduction in risk probably reﬂ ects improved 
anaesthetic and surgical techniques, and improved 
medical treatment before surgery. The low rate of 
myocardial infarction in our trial is consistent with 
improved medical treatment before surgery.
Our results are applicable to the current practice of 
carotid stenting at most vascular centres. The 
participating centres were representative of academic 
centres with substantial experience of treating carotid 
stenosis and needed to show a high standard of practice 
before they could join the trial. Our results could be 
criticised in that the experience of the interventionists in 
carotid stenting was less than that of the surgeons in 
carotid endarterectomy. However, the risk of outcome 
events associated with stenting was lower in in-
experienced, supervised centres than in more experienced 
centres (ﬁ gure 4) and there was no signiﬁ cant diﬀ erence 
in the excess hazard of stenting compared with 
endarterectomy between supervised and experienced 
centres or between centres recruiting more or less than 
50 patients; therefore, inexperience cannot explain our 
results. The EVA-3S trial also showed no diﬀ erences in 
the outcomes favouring endarterectomy related to the 
experience of the interventionists or the number of 
procedures done within the trial.5 
There are several possible explanations for the excess 
of non-disabling stroke seen in the stenting group 
compared with the endarterectomy group. Investigators 
who undertook follow-up assessments were not masked 
to treatment allocation, leading to the possibility of 
ascertainment bias of minor events. A post-analysis 
audit has conﬁ rmed that all but 77 patients were seen 
for follow-up by a neurologist or stroke physician, or by 
research nurses or practitioners supervised by a 
neurologist, not directly involved in the revascularisation 
procedures. A sensitivity analysis excluding the 
77 patients seen for follow-up by a surgeon only, provided 
similar results to those of the full analysis (data not 
shown), making it unlikely that biased reporting aﬀ ected 
the results. We were concerned that some short-lived 
events might be missed in surgical patients operated on 
under general anaesthesia and returned to surgical 
wards, whereas these events might not be missed in 
endovascular patients treated under local anaesthesia. 
However, this hypothesis is an unlikely explanation of 
our results, since most of the excess non-disabling 
strokes associated with stents lasted for more than 7 
days. The conclusion that the excess in non-disabling 
stroke cannot be explained by bias is supported by the 
results of a blinded MRI subanalysis of this trial.15 This 
subanalysis showed a signiﬁ cantly higher proportion of 
patients with new ischaemic lesions on MRI in the 
stenting group than in the endarterectomy group (50% 
vs 17%, adjusted odds ratio 5∙21, 95% CI 2∙78–9∙79, 
p<0∙0001). 
The most likely explanation for the excess risk of non-
disabling stroke associated with stenting is that it is 
related to instrumentation of the carotid stenosis, given 
that most strokes occurred on the day of treatment. 
Selection of patients could be important in keeping the 
risks of instrumentation to a minimum. Future analyses 
Figure 5: Meta-analysis comparing safety of carotid artery stenting with endarterectomy in the recent carotid stenting trials
Odds ratio for any stroke, death, or procedural myocardial infarction within 30 days of treatment in the three recent trials of carotid artery stenting versus 
endarterectomy including only symptomatic patients. Analysis is based on published results of per-protocol data. The large diamond represents the odds ratio and 
95% CI of the combined data. The summary estimate statistic was calculated by use of a Mantel-Haenszel ﬁ xed-eﬀ ect model; the centre of the diamond is the point 
estimate, and its width the 95% CI. EVA-3S=Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis. SPACE=Stent-Protected 
Angioplasty versus Carotid Endarterectomy. ICSS=International Carotid Stenting Study.
EVA-355
SPACE6
ICSS
Total
Heterogeneity: χ2=2·42, df=2 (p=0·30); I2=17%
Test for overall eﬀect: Z=3·69 (p=0·0002)
26
42
61
129
2008
2008
2010
Year
Events Number of
patients
Weight Odds ratio (95% CI)
Favours stenting
0·01 0·1 1 10 100
Favours endarterectomy
265
573
828
1666
11
32
33
76
262
563
821
1646
 14·1%
 42·4%
 43·5%
100·0%
2·48 (1·20–5·13)
1·31 (0·82–2·11)
1·90 (1·23–2·93)
1·73 (1·29–2·32)
Carotid stenting Carotid endarterectomy
Events Number of
patients
Articles
www.thelancet.com   Vol 375   March 20, 2010 995
of our trial will investigate anatomical and clinical risk 
factors for procedural stroke, as well as the eﬀ ects of 
stent design and protection devices.
Our exploratory analyses suggested that carotid stenting 
might have a similar risk to endarterectomy in women, 
but that the intervention was more hazardous than 
endarterectomy in men. However, the diﬀ erence between 
the hazard ratios comparing stenting with endarterectomy 
in women and men did not reach statistical signiﬁ cance. 
The diﬀ erence seemed to be largely explained by a higher 
risk of outcome events associated with endarterectomy in 
women than in men. The increased risk associated with 
endarterectomy in women is a consistent feature of most 
large studies and was also seen in the EVA-3S trial,8 in 
the pooled analysis of the major carotid endarterectomy 
trials,16 and in a systematic review of the published 
series.17 Stenting seemed to be more hazardous, and 
endarterectomy less hazardous, in patients without 
treated hypertension at baseline than in patients with 
treated hypertension, but the reasons remain unclear. 
However, a systematic review of predictors of stroke and 
death caused by carotid endarterectomy showed a similar 
increase in risk of stroke or death associated with 
hypertension (HR 1·82, 95% CI 1·37–2·41, p<0·0001) in 
accordance with our ﬁ ndings.18
Our results suggest that carotid endarterectomy should 
remain the treatment of choice for symptomatic patients 
with severe carotid stenosis suitable for surgery. Most 
patients had no complications from either procedure. 
Thus, some patients might still opt for stenting after 
being presented with the available evidence, especially if 
they have a strong preference for avoiding surgery. Since 
outcomes in the stenting group were similar to those 
reported after carotid endarterectomy in previous trials 
that compared surgery with best medical treatment 
alone, stenting is also likely to be better than no 
revascularisation in patients unwilling or unable to have 
surgery because of medical or anatomical 
contraindications.
The aim of treatment for carotid stenosis is long-term 
prevention of stroke. The EVA-3S and SPACE studies 
showed little diﬀ erence between carotid stenting and 
endarterectomy groups in the rates of ipsilateral non-
perioperative stroke occurring more than 30 days after 
treatment, but the length of follow-up in these studies 
was restricted to a maximum of 4 years and 2 years, 
respectively.7,8 CAVATAS had a longer follow-up period 
and reported a higher 8-year rate of non-perioperative 
stroke in patients who received endovascular treatment 
(21·1%) than in patients who received surgery (15·4%; 
HR 1·66, 95% CI 0·99–2·80).12 Most of the divergence 
occurred more than 2 years after randomisation, which 
might be partly explained by a higher incidence of 
restenosis after endovascular treatment than after 
endarterectomy.19 However, CAVATAS included only a 
small proportion of patients treated by use of a stent, and 
the long-term rate of restenosis after stent insertion 
remains uncertain. Follow-up is therefore continuing in 
ICSS and further data will become available from the trial 
in due course.
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